Mundipharma has closed an asset purchase agreement with Vital Food Processors Limited, an agricultural science company founded in New Zealand, for the global rights beyond New Zealand to commercialise Zyactinase™ — a clinically-proven gastrointestinal consumer health product.
Zyactinase™ is a freeze-dried extract of Kiwifruit (Actinidia deliciosa) that has been developed as a constipation relief product as well as for long-term gut health. It contains a protease complex, fiber, pectin and fructo-oligosaccharides that stimulates increased bowel movements.
Under the agreement, Mundipharma will initially focus on the commercialising Zyactinase™ to establish a foothold in the US and Canada markets, while continuing to supply existing partners. It will then look to expand its marketing and distribution footprint globally.
This agreement will also enable the extension of the company’s Senokot® product range in the US, which is also an all natural, clinically proven digestive health supplement for the treatment of constipation.
“We are delighted to have realised this opportunity to acquire a unique, clinically-proven differentiated formulation for commercialisation on a global basis across our network,” said Mundipharma CEO, Raman Singh.
“As well as providing a consumer pathway for a great product, this strategic acquisition also enables us to extend our depth and competitiveness in the digestive health category,” he added.
Dr Oliver Summerfield, Vital Foods CEO and Principal at majority investor Inventages Venture Capital, commented “We believe this deal recognises the value created by Vital Foods’ technology platform and that Mudipharma are a strong partner for the global commercialisation of the clinically-proven digestive health product developed by Vital Foods’ team.”
TM: ZYACTINASE is a trademark of Vital Food
®: SENOKOT is a registered trademark of Purdue in the US.
Zyactinase is reputed to be one of the most effective, gentle laxative therapies currently available. Zyactinase™ is a 100% natural product derived from New Zealand kiwifruit using Vital Foods’ proprietary processing technology with no artificial ingredients. Products formulated with Zyactinase™, including Phloe and Kivia capsules and chewable tablets. Seven separate clinical studies have confirmed that Zyactinase™ formulations improve general digestive health, normalise bowel function, reduce bloating, minimise episodes of occasional constipation, and assist in reducing abdominal pain and discomfort. Zyactinase™ formulations have none of the side effects commonly associated with harsher laxatives.
About Vital Foods
Vital Foods’ was established to provide the digestive health benefits of kiwifruit through easy to consume digestive health products for all ages. The company’s first product on the market was Kiwi Crush™, a frozen kiwifruit drink that is made available to most patients in hospitals and nursing home in New Zealand and is sold as a digestive aid in supermarkets in New Zealand. Vital Foods was formed by two dedicated kiwifruit industry experts and launched by a group of committed local New Zealand investors. Since 2006, Vital Foods’ Research & Development efforts have been financed through a sophisticated syndicate that is predominantly comprised of Inventages Venture Capital and BioPacific Ventures.
Mundipharma’s independent associated companies are privately owned entities covering the world’s pharmaceutical markets. Mundipharma is a prime example of a company that consistently delivers high quality products while standing by the values that represent the company. Our mission is to alleviate the suffering of patients with cancer and non-cancer pain and to substantially improve their quality of life. Mundipharma is dedicated to bringing to patients with severe and debilitating diseases the benefit of novel treatment options in fields such as pain, oncology, oncology supportive care, ophthalmology, respiratory disease and consumer healthcare, including Upper Respiratory Care, Digestive Wellness, Feminine Care, Wound Care and Infection Protection.
The development was reported by prnewswire.com